Evidence map›Paper›PMID 30758786›Full record

ArticleHepatology international2019

Management of HCV-related decompensated cirrhosis with direct-acting antiviral agents: who should be treated?

Amr Shaaban Hanafy, Mohamed A Bassiony, Mohammad Abd Alkhalik Basha

Registry-linked trialAbstract read
PubMed Publisher
In one paragraph

Article in Hepatology international, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03547895 (Real Life Experience in the Management of HCV Related Decompensated Cirrhosis With Direct Antiviral Agents), which is not on this map. Cited by 11 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 3 pooled it
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03547895 nacompletednot on this map

Real Life Experience in the Management of HCV Related Decompensated Cirrhosis With Direct Antiviral Agents

TypeinterventionalSponsorZagazig UniversityRan2015 to 2018Enrolled80ConditionsDecompensated CirrhosisArmsSofosbuvir 400mg (Sovaldi) + Daclatasvir 60 mg (Daklinza) + Ribavirin 200 mg (Rebetol), vitamin K (Phytomenadione) 10 mg+ furosemide and spironolactone (Lasilactone) 50 mg + milk thistle (Silymarin) 140 mg + Albumin infusion
3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 3 syntheses or guidelines pooled it, 19 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Review
  5. Review
  6. Review
  7. Article
  8. Review
  9. [Reversal of cirrhotic decompensation: re-compensation].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2019
    Article
  10. [Progress of antiviral therapy for hepatitis C virus-related decompensated cirrhosis].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2019
    Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Amr Shaaban HanafyInternal Medicine Department, Hepatology Division, Zagazig University, Sharkia, Zagazig, 44519, Egypt. Dr_amr_hanafy@yahoo.com.ORCID http://orcid.org/0000-0003-2901-2614
Mohamed A BassionyInternal Medicine Department, Hepatology Division, Zagazig University, Sharkia, Zagazig, 44519, Egypt.
Mohammad Abd Alkhalik BashaDiagnostic Radiology, Zagazig University, Zagazig, Egypt.
Zagazig University · EG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMedical treatment of decompensated cirrhosis due to hepatitis C virus (HCV) remains a clinical challenge even in the era of direct-acting antiviral drugs (DAAs). We evaluated the efficacy and safety of DAAs in the management of HCV genotype 4-related decompensated cirrhosis.

methodsThe study included a treatment group (n = 160) composed of HCV patients with decompensated cirrhosis who received DAAs for 3 months and a matched control group (n = 80) who preferred not to receive DAAs, follow-up was for 24-31 months.

resultsIn treatment group; there were improvements in platelet count, albumin, CTP (p = 0.001) and MELD scores (p = 0.03), a significant reduction in the frequency of hepatic encephalopathy (HE). SVR was achieved in 90%. Hepatocellular carcinoma (HCC) developed in 10% (n = 18) within 6.8 ± 2.5 months after DAAs, survival was higher in the treated vs. the control group (28.9 ± 0.95 vs. 11.4 ± 2.2 months, p = 0.001). Liver volume by ultrasound at a cutoff 495 ml was predictive of complications after DAAs therapy mainly HCC and reduced survival with sensitivity 93.2%, specificity 72%.

conclusionHCV with decompensated cirrhosis and adequate liver volume had a 90% SVR with improved CTP&MELD and survival. CLINICAL TRIAL: (NCT03547895).

Indexed as

AdultAntiviral AgentsAscitesCarbamatesDrug Therapy, CombinationEsophageal and Gastric VaricesFemaleHepatic EncephalopathyHepatitis C, ChronicHumansImidazolesLiver CirrhosisMaleMiddle AgedPatient SelectionPyrrolidinesAntiviral AgentsCarbamatesdaclatasvirImidazolesPyrrolidinesRibavirinRNA, ViralSofosbuvirValineDAAsDecompensated cirrhosisHCVLiver volume

Identifiers

PMID30758786
OpenAlexW2914799449

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.